I agree. There are also factors related only to trial conduct that affects the analysis. For example, about 10% of the 9902a treatment arm did not get fully treated. That got to have some confounding effect on the final results. Hopefully IMPACT will do better with that. In addition, with a much larger enrollment number, the imbalances will be less pronounced.
ignorance is bliss I guess :) You epitomize my characterization of managment's attitude- I'm sure Gold is comfortable too and I would speculate that Small is annoyed or even disgruntled. You should never be complacent, especially given the data and theory "we" have right now. Maybe Gold has a secret source of insight into this matter and feel's that the company's core proprietary cassette is as good as it gets but even in this case he hasn't done a good job convincing anyone else of the product's value.
Since you seemed to pick out a few cancer related problems you apparently have at least skimmed the lit. Take a look at history and current status of immunotherapy and tell me why you are comfortable.
Market Data 
Markets 
AI
